Summary
Eli Lilly and Company (LLY) announced on February 24, 2015, that it entered into an underwriting agreement for the issuance and sale of a significant debt offering. The company is raising a total of $2.2 billion through the sale of three tranches of notes: $600 million of 1.250% Notes due 2018, $800 million of 2.750% Notes due 2025, and $800 million of 3.700% Notes due 2045. This substantial debt issuance indicates the company's strategy to secure funding, potentially for ongoing research and development, capital expenditures, or other corporate initiatives. Investors should note the specific interest rates and maturity dates for each tranche of notes, as these terms dictate the cost of borrowing for Lilly and the repayment schedule. The offering is registered under a Form S-3 and is expected to close on March 5, 2015, with net proceeds anticipated to be approximately $2.18 billion after underwriter discounts. The filing also outlines the conditions under which the principal amount of the notes could be declared due and payable, as well as Lilly's option to redeem the notes.
Key Highlights
- 1Eli Lilly issued $2.2 billion in new debt across three tranches of notes with varying interest rates and maturity dates.
- 2The notes include $600 million of 1.250% Notes due 2018, $800 million of 2.750% Notes due 2025, and $800 million of 3.700% Notes due 2045.
- 3The debt offering is intended to provide significant capital for the company's operations or strategic initiatives.
- 4The offering is registered under a Form S-3 (File No. 333-186979), indicating prior SEC review.
- 5The expected closing date for the offering is March 5, 2015.
- 6The company anticipates net proceeds of approximately $2.18 billion after deducting underwriter discounts.
- 7The filing details terms related to default events and the company's option for early redemption of the notes.